Primary Hyperoxaluria Market Infographics
Primary Hyperoxaluria Market

Primary Hyperoxaluria is a rare genetic disease caused by deficiencies in glyoxylate metabolism. It is a rare genetic disease caused by deficiencies in glyoxylate metabolism. It is characterized by increased urinary excretion of oxalate. It can be caused by genetic mutations that result in oxalate overproduction (primary hyperoxaluria) or enteric hyperoxaluria, which can occur due to malabsorptive states and/or less well-understood genetic causes.


Primary Hyperoxaluria Epidemiology Segmentation in 7MM from 2018 to 2030


  • Primary Hyperoxaluria Prevalent Cases
  • Primary Hyperoxaluria Diagnosed Prevalent Cases
  • Primary Hyperoxaluria Gender-specific Diagnosed Prevalent Cases
  • Primary Hyperoxaluria Age-specific Diagnosed Prevalent Cases
  • Primary Hyperoxaluria Type-specific Diagnosed Prevalent Cases


Primary Hyperoxaluria Epidemiology Insights Observed in 2020


  • The Total Primary Hyperoxaluria prevalent population in the 7MM was observed to be 11,918, and the Primary Hyperoxaluria diagnosed prevalent population in the US was found to be 2,327, whereas in the UK it was 198, and Germany was 171, also in Japan, there were 81 cases.
  • The total Primary Hyperoxaluria diagnosed prevalent cases in Males in Japan were found to be 48 whereas in females they were found to be 33.
  • Primary Hyperoxaluria Type 1 specific Diagnosed Prevalent Cases in the US was estimated to be 1,629.


Primary Hyperoxaluria Market Insights


The Primary Hyperoxaluria Market is expected to grow at a significant CAGR of USD 19 million during the study period (2018-30).


Primary Hyperoxaluria Market Drivers


  • Current and future changes in the paradigm of therapies
  • Entry of approved therapy
  • Future potentials of emerging treatment
  • Increasing prevalence
  • Global exposure


Primary Hyperoxaluria Market Barriers


  • Lack of available long-term data
  • Delayed diagnosis
  • Challenging disease in terms of management
  • Lack of robust pipeline


Primary Hyperoxaluria Emerging Therapies


The emerging drugs in the Primary Hyperoxaluria market are 

  • Oxabact (OC5-DB-02)
  • Nedosiran (DCR-PHXC)
  • RELOXALIASE (ALLN-177)
  • Stiripentol (Diacomit)


Primary Hyperoxaluria Key Players


The key companies in the Primary Hyperoxaluria market are 

  • Biocodex
  • Allena Pharmaceuticals
  • Dicerna Pharmaceuticals, Inc.
  • OxThera